Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
Boehringer Ingelheim's pan-KRAS program promises preclinical data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, USA...
Oct 31